Liver Cirrhosis: Mechanisms to Malfunction – The Pathophysiology of the Clinical Manifestations

ARGH.MS.ID.556086

Our Media Partner

 

ARGH Menu

 

Useful Links

 

Downloads

  • #   #   #

Review Article

Liver Cirrhosis: Mechanisms to Malfunction – The Pathophysiology of the Clinical Manifestations

Harshal Rajekar1* and Ayushi Joshi2

1Department of GI, HPB and General Surgery Medicover Hospitals, Indrayani Nagar Road, Bhosari, Pimpri Chinchwad, Pune, India

2Consultant Hepatobiliary, Gastrointestinal and Liver Transplant Surgeon, India

Submission:March 01, 2026;Published:March 12, 2026

*Corresponding author:Harshal Rajekar, Department of GI, HPB and General Surgery Medicover Hospitals, Indrayani Nagar Road, Bhosari, Pimpri Chinchwad, Pune, India

How to cite this article:Harshal R, Ayushi J. Liver Cirrhosis: Mechanisms to Malfunction – The Pathophysiology of the Clinical Manifestations. Adv Res Gastroentero Hepatol, 2026; 22(3): 556086.DOI: 10.19080/ARGH.2026.22.556086.

Abstract

Background and Aims: Liver cirrhosis represents the final common pathway of chronic liver injury, characterized by progressive fibrosis, vascular remodeling, and hepatocellular dysfunction. This review aims to comprehensively detail the pathophysiology linking these structural changes to the spectrum of clinical manifestations, from portal hypertension to hepatocellular carcinoma.
Methods: We conducted a narrative review of the literature, synthesizing current knowledge on the molecular, hemodynamic, and systemic pathways involved.
Results: The central hemodynamic derangement is portal hypertension, arising from increased intrahepatic resistance (due to fibrosis, sinusoidal dysfunction, and hepatic stellate cell activation) and aggravated by splanchnic vasodilation. This drives ascites formation via neurohumoral activation and renal sodium retention. Hepatic encephalopathy results from ammonia toxicity, neurotransmitter imbalance, and systemic inflammation exacerbated by gut-brain axis disruption. Coagulopathy in cirrhosis is a “rebalanced” but fragile state. Complications like spontaneous bacterial peritonitis and hepatorenal syndrome stem from gut-liver axis dysfunction and circulatory collapse. The cirrhotic microenvironment, rich in inflammation and oxidative stress, is profoundly oncogenic, driving hepatocellular carcinoma.
Conclusions: The clinical manifestations of cirrhosis are interconnected outcomes of a systemic disorder. Understanding this integrated pathophysiology is crucial for developing targeted therapies that move beyond symptom management to modify the disease course.

Keywords:Liver cirrhosis; Portal hypertension; Hepatic encephalopathy; Ascites; Coagulopathy; Hepatorenal syndrome; Hepatocellular carcinoma; Pathophysiology; Fibrosis; Inflammation

Abbreviations:NAFLD: Non-Alcoholic Fatty Liver Disease; SBP: Spontaneous Bacterial Peritonitis; HRS: Hepatorenal Syndrome; HCC: Hepatocellular Carcinoma; HVPG: Hepatic Venous Pressure Gradient; ECM: Extracellular Matrix; HSC: Hepatic Stellate Cell; LSEC: Liver Sinusoidal Endothelial Cells; NO: Nitric Oxide; RAAS: Renin-Angiotensin-Aldosterone System; SNS: Sympathetic Nervous System; AVP: Arginine Vasopressin; VEGF: Vascular Endothelial Growth Factor; PDGF: Platelet-Derived Growth Factor; TIPS: Transjugular Intrahepatic Portosystemic Shunt; BSEP: Bile Salt Export Pump; GFR: Glomerular Filtration Rate; HE: Hepatic Encephalopathy; BBB: Blood–Brain Barrier; FMT: Fecal Microbiota Transplantation; MRS: Magnetic Resonance Spectroscopy; LOLA: L-Ornithine L-Aspartate; TPA: Tissue Plasminogen Activator; PVT: Portal Vein Thrombosis; TAFI: Thrombin-Activatable Fibrinolysis Inhibitor; DOACs: Direct Oral Anticoagulants; CAID: Cirrhosis-Associated Immune Dysfunction; MDSC: Myeloid-Derived Suppressor Cells; HGF: Hepatocyte Growth Factor; ROS: Reactive Oxygen Species; SASP: Senescence- Associated Secretory Phenotype

Introduction

Cirrhosis is a dynamic, progressive disease resulting from chronic liver injury due to viral hepatitis, alcohol, non-alcoholic fatty liver disease (NAFLD/MASLD), autoimmune disorders, and other causes [1-4]. Characterized histologically by regenerative nodules surrounded by fibrotic septa, cirrhosis leads to architectural distortion of the liver parenchyma, sinusoidal capillarization, and altered hepatic blood flow [5-8]. This structural damage has profound systemic consequences, mediated primarily through the development of portal hypertension, neurohumoral activation, immune dysregulation, and metabolic derangements [9, 10]. The clinical spectrum ranges from compensated, asymptomatic cirrhosis to decompensated cirrhosis, which manifests with lifethreatening complications such as ascites, variceal hemorrhage, jaundice, hepatic encephalopathy, and coagulopathy [11-13]. This transition to decompensation marks a critical worsening of prognosis [14]. Furthermore, cirrhosis predisposes patients to multi-organ complications including spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), and hepatocellular carcinoma (HCC) [15-17]. This article provides a comprehensive pathophysiological review of the underlying mechanisms responsible for all major clinical manifestations of cirrhosis. We aim to construct a detailed roadmap linking initial hepatic injury and subsequent structural changes to the systemic clinical sequelae. Emphasis is placed on elucidating molecular mechanisms, hemodynamic alterations, neurohumoral pathways, and translational insights that inform current management and underpin emerging therapeutic strategies targeting the root causes of this complex disease.

Pathophysiology of Portal Hypertension

Portal hypertension is the principal hemodynamic complication of cirrhosis, defined as a sustained increase in portal venous pressure. A hepatic venous pressure gradient (HVPG) above 5 mmHg indicates portal hypertension, with clinically significant portal hypertension present at ≥10–12 mmHg [18- 20]. Its pathogenesis is multifactorial, encompassing structural, vascular, and dynamic components that increase both intrahepatic resistance and portal venous inflow.

Structural Factors and Increased Intrahepatic Resistance

Structural changes in cirrhosis are the primary initiators of increased resistance. These include fibrotic septa formation, regenerative nodules, and sinusoidal capillarization, which collectively distort and obstruct the hepatic microvasculature [5-7, 21]. The key cellular driver is the hepatic stellate cell (HSC). Upon activation by inflammatory mediators (e.g., TGF-β, PDGF), HSCs undergo a myofibroblastic transformation, proliferate, and become the main producers of extracellular matrix (ECM) proteins such as type I and III collagen, laminin, and fibronectin, reinforcing fibrotic barriers to blood flow [22-24]. Concurrently, sinusoidal endothelial dysfunction is critical. Liver sinusoidal endothelial cells (LSECs) lose their characteristic fenestrations in a process called capillarization, deposit a basement membrane, and exhibit impaired production of vasodilators like nitric oxide (NO) while increasing production of vasoconstrictors such as endothelin-1 (ET-1) [25,26]. This endothelial phenotype shift directly contributes to increased intrahepatic tone and resistance.

Dynamic Factors and Intrahepatic Vasoconstriction

Beyond fixed structural impediments, a dynamic, reversible component of intrahepatic vasoconstriction accounts for a significant proportion of resistance. An imbalance between vasoconstrictors (endothelin-1, angiotensin II, thromboxane A2) and vasodilators (NO, prostacyclin) modulates sinusoidal tone, amplifying portal pressure [25-27]. Activated, contractile HSCs express α-smooth muscle actin and respond to these mediators, contracting and further narrowing the sinusoidal lumen [28]. Microvascular thrombosis within sinusoids, driven by a prothrombotic milieu, also exacerbates resistance and can contribute to parenchymal extinction and fibrosis progression [29, 30].

Splanchnic Arterial Vasodilation and Hyperdynamic Circulation

Splanchnic vasodilation is a compensatory yet pathological response that worsens portal hypertension by increasing portal venous inflow. It is driven by excessive NO production in mesenteric vessels, largely stimulated by shear stress and bacterial endotoxin (lipopolysaccharide, LPS) activating inducible nitric oxide synthase (iNOS) [31, 32]. This leads to a reduction in systemic vascular resistance. The resultant state of effective arterial underfilling or hypovolemia is sensed by baroreceptors, triggering the activation of potent vasoconstrictor and sodiumretentive systems: the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system (SNS), and non-osmotic arginine vasopressin (AVP) release [33-35]. The combined effect is renal sodium and water retention, leading to plasma volume expansion. However, due to persistent splanchnic vasodilation, this expanded volume primarily pools in the splanchnic circulation, further increasing portal venous inflow and perpetuating portal hypertension-a central tenet of the “peripheral arterial vasodilation hypothesis” [36]. This cycle creates a hyperdynamic circulatory state characterized by increased cardiac output, tachycardia, and low systemic vascular resistance [37].

Collateral Formation and Varices

Persistent portal hypertension induces angiogenesis and the development of portosystemic collaterals [38, 39]. The most clinically significant are gastroesophageal varices. Their formation is driven by angiogenic factors such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which are upregulated by portal hypertension and hypoxia [40, 41]. While these collaterals provide partial decompression of the portal system, they predispose to variceal hemorrhage, a major cause of morbidity and mortality [42, 43].

Molecular Insights and Signaling Pathways

At the molecular level, interactions between HSCs, LSECs, and Kupffer cells via paracrine signaling reinforce fibrogenesis and vascular remodeling. Key pathways include:
a) TGF-β/SMAD: The master fibro genic pathway driving HSC activation and ECM production [22, 44].
b) PDGF Signaling: The primary mitogenic pathway for HSC proliferation [24].
c) Hedgehog Signaling: Involved in HSC activation and angiogenesis [45].
d) TLR4/NF-κB Pathway: Gut-derived endotoxins (LPS) activate Toll-like receptor 4 (TLR4) on Kupffer cells and HSCs, promoting inflammation, stellate cell activation, and ET-1 expression, linking the gut-liver axis to portal hypertension [46- 48].

Reactive oxygen species (ROS) derived from NADPH oxidase and mitochondrial dysfunction amplify these effects, creating a pro-fibrotic and pro-contractile milieu [49, 50].

Clinical and Therapeutic Implications

Understanding this integrated model explains the rationale for therapies. Non-selective β-blockers (e.g., propranolol, carvedilol) reduce portal pressure by decreasing cardiac output (β1-blockade) and inducing unopposed α-adrenergic-mediated splanchnic vasoconstriction (β2-blockade) [51]. Endoscopic variceal ligation is used for primary and secondary prophylaxis of bleeding. For refractory variceal bleeding or ascites, the transjugular intrahepatic portosystemic shunt (TIPS) directly reduces portal pressure by creating a low-resistance channel between the hepatic and portal veins [52]. Emerging therapies target the molecular drivers, such as statins to improve LSEC function and NO availability, and antifibrotic agents aimed at the dynamic components of resistance [53, 54].

Mechanisms of Jaundice, Ascites, and Edema

Pathophysiology of Jaundice

Jaundice, the yellow discoloration of skin and sclera, reflects hyperbilirubinemia resulting from impaired hepatic uptake, conjugation, or excretion of bilirubin [55]. In cirrhosis, the principal mechanism is intrahepatic cholestasis secondary to hepatocellular dysfunction and architectural distortion that impedes bile flow [56, 57]. The process involves defects at multiple levels of bilirubin metabolism. Hepatocyte injury disrupts the basolateral uptake of unconjugated bilirubin. This uptake is primarily mediated by organic anion transporting polypeptides (OATP1B1/1B3) and the sodium-taurocholate co-transporting polypeptide (NTCP), whose expression and function are downregulated in cirrhosis [58, 59]. Within the hepatocyte, bilirubin conjugation by uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1) is often relatively preserved until late stages [60]. However, the canalicular excretion of conjugated bilirubin is severely impaired.

This critical step is mediated by the multidrug resistanceassociated protein 2 (MRP2) and the bile salt export pump (BSEP). Their expression and trafficking to the canalicular membrane are disrupted by oxidative stress, inflammatory cytokines (e.g., TNF-α, IL-6), and cytoskeletal damage [61,62]. Pro-inflammatory cytokines downregulate these transporters via NF-κB-dependent mechanisms [63,64]. Furthermore, mechanical compression of bile canaliculi by fibrous septa and regenerative nodules creates a physical barrier to bile flow [57,65]. The resultant regurgitation of bile acids and conjugated bilirubin into the systemic circulation contributes not only to jaundice but also to pruritus and direct hepatocellular toxicity [66,67]. The severity of hyperbilirubinemia correlates closely with the degree of hepatocellular synthetic failure and is a key prognostic component of the Child-Pugh and MELD scores [68, 69].

Pathophysiology of Ascites

Ascites is the most frequent complication of cirrhosis, occurring in nearly 60% of patients within 10 years of diagnosis [70]. It represents the pathophysiological consequence of portal hypertension, arterial vasodilation, and renal sodium retentionthe so-called “forward” and “backward” theories integrated into a sequential model [71,72]. The initiating event is an increase in sinusoidal hydrostatic pressure due to portal hypertension. This promotes the transudation of a protein-poor fluid into the space of Disse and subsequently into the peritoneal cavity. This process is amplified by sinusoidal capillarization and increased vascular permeability mediated by factors like vascular endothelial growth factor (VEGF) [73,74]. Concurrently, splanchnic arterial vasodilation causes a fall in effective arterial blood volume. This arterial underfilling activates the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system (SNS), and triggers the non-osmotic release of arginine vasopressin (AVP) [75-78]. The combined effect of these neurohumoral systems is enhanced renal sodium and water retention. The expanded plasma volume, due to persistent vasodilation and high capillary pressure, leads to further fluid transudation and progressive accumulation of ascitic fluid.

At the renal level, increased sympathetic tone and angiotensin II cause renal vasoconstriction, reducing renal perfusion and glomerular filtration rate (GFR), which predisposes to hepatorenal syndrome (HRS) in advanced disease [79,80]. Renal Doppler studies demonstrate decreased renal cortical perfusion proportional to the severity of portal hypertension [81,82]. Systemic inflammation plays a pivotal modulating role. Bacterial translocation from the gut increases circulating lipopolysaccharide (LPS) levels, stimulating the release of cytokines (TNF-α, IL-6) that worsen splanchnic vasodilation and endothelial dysfunction [48,83]. This inflammatory milieu perpetuates fluid retention and predisposes to spontaneous bacterial peritonitis (SBP). The composition of ascitic fluid reflects its pathogenesis: a high serum-ascites albumin gradient (SAAG >1.1 g/dL) confirms portal hypertension as the primary driver, while low protein content (<1.5 g/dL) is associated with diminished opsonic activity and increased infection risk [84, 85].

Peripheral Edema

Peripheral edema in cirrhosis shares a similar pathogenesis with ascites but is more influenced by systemic capillary dynamics. Hypoalbuminemia due to impaired hepatic synthetic function reduces plasma oncotic pressure, facilitating the extravasation of fluid into the interstitial space [86,87]. Simultaneously, the neurohumoral activation (RAAS, AVP) promotes sodium and water retention, expanding extracellular volume. The net result is dependent pitting edema, typically in the lower extremities. In advanced stages, lymphatic drainage becomes overwhelmed, further worsening edema [88]. While albumin administration can transiently improve oncotic pressure, its benefits are short-lived without addressing the underlying hemodynamic derangements [89].

Integrated Mechanistic Model and Clinical Implications

The pathophysiology of ascites and edema thus represents a complex interplay between portal hypertension, systemic vasodilation, neurohumoral activation, and impaired oncotic regulation [90]. This aligns with the “arterial underfilling hypothesis,” where decreased effective arterial volume triggers a vicious cycle [36]. The onset of ascites marks a key transition from compensated to decompensated disease, with a median survival of approximately two years without liver transplantation [91]. Management strategies directly target these pathways: sodium restriction, diuretics (spironolactone to antagonize aldosterone, furosemide for loop diuresis), and albumin infusion to improve circulatory function [92,93]. For refractory ascites, large-volume paracentesis with albumin replacement and TIPS placement to decompress the portal system are effective therapeutic options [94]. Understanding these integrated pathways continues to guide the development of new interventions, such as vasoconstrictors (midodrine, terlipressin) to counteract splanchnic vasodilation [95,96].

Hepatic Encephalopathy

Hepatic encephalopathy (HE) represents a spectrum of neuropsychiatric abnormalities resulting from advanced hepatic dysfunction and portosystemic shunting [97,98]. Clinically, it ranges from subtle cognitive impairment (minimal HE) to deep coma and is characterized by reversible disturbances in consciousness, behavior, and neuromotor function [99,100]. The underlying pathophysiology is multifactorial, involving ammonia accumulation, astrocyte dysfunction, altered neurotransmission, systemic inflammation, and gut-brain axis disruption [101-103].

Central Role of Ammonia

Ammonia is a principal neurotoxin in HE. Under normal conditions, hepatocytes detoxify ammonia through the urea cycle and glutamine synthesis [104]. In cirrhosis, loss of functional hepatic mass and portosystemic shunting result in impaired ammonia clearance, leading to systemic hyperammonemia [105,106]. Elevated blood ammonia crosses the blood–brain barrier (BBB) via specific transporters (Rh glycoproteins) and passive diffusion [107]. Within the brain, ammonia is metabolized by astrocytic glutamine synthetase, producing glutamine. The intracellular accumulation of glutamine acts as an osmolyte, leading to astrocytic swelling, cerebral edema (particularly in acute liver failure), and the characteristic Alzheimer type II histologic change seen in chronic HE [108,109]. This swelling disrupts astrocyteneuron metabolic coupling, impairs neurotransmitter recycling, and promotes oxidative stress and mitochondrial dysfunction [110].

Neurotransmitter Imbalance

Ammonia toxicity alters the balance of excitatory and inhibitory neurotransmission.
I. Increased GABAergic Tone: Ammonia promotes the synthesis of neurosteroids (e.g., allopregnanolone) in astrocytes, which are potent positive allosteric modulators of GABA-A receptors. This enhanced GABAergic inhibition contributes to the neuronal depression, lethargy, and coma characteristic of HE [111,112].
II. Glutamatergic Dysfunction: Disruption of the glutamate-glutamine cycle between astrocytes and neurons leads to reduced synaptic availability of glutamate, the primary excitatory neurotransmitter, impairing cognition and alertness [113].
III. Other Systems: Elevated ammonia and manganese accumulation can disrupt dopaminergic and serotonergic pathways in the basal ganglia, contributing to extrapyramidal symptoms like parkinsonism observed in chronic HE (acquired hypercerebral degeneration) [114,115].

Synergistic Role of Systemic Inflammation and Oxidative Stress

Systemic inflammation profoundly modulates HE severity and is often the precipitant of acute episodes. Inflammation triggered by bacterial translocation or infections (e.g., spontaneous bacterial peritonitis) increases BBB permeability and potentiates ammonia-induced neurotoxicity [116,117]. Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) induce microglial activation and further promote neuroinflammation [118,119]. Ammonia itself can enhance NMDA receptor activation, increasing intracellular calcium and reactive oxygen species (ROS) production, leading to oxidative stress and neuronal injury [120]. This synergistic “double-hit” model (ammonia + inflammation) explains why treatments targeting inflammation can improve HE [121,122].

Gut–Liver–Brain Axis

Emerging evidence underscores the gut microbiota as a major modulator of HE [123,124]. Dysbiosis in cirrhosis favors ureaseproducing and ammonia genic bacteria (e.g., Klebsiella, Proteus) and increases intestinal permeability [125,126]. This leads to elevated production and absorption of ammonia, endotoxins (LPS), and other neuroactive metabolites (e.g., short-chain fatty acids, phenols) [127,128]. These gut-derived factors fuel systemic inflammation and directly or indirectly affect brain function. Therapeutic interventions like lactulose and rifaximin act primarily on this axis. Lactulose works via osmotic catharsis and by acidifying the colonic lumen, trapping ammonia as ammonium ions, and acting as a prebiotic to promote beneficial bacteria [129]. Rifaximin, a non-absorbable antibiotic, modulates the gut microbiome, reduces bacterial translocation and endotoxin load, and is proven to prevent HE recurrence [130,131]. Studies on probiotics and fecal microbiota transplantation (FMT) suggest additional benefits via restoration of microbial diversity and gut barrier integrity, highlighting the therapeutic potential of targeting the microbiome [132-134].

Astrocytic and Mitochondrial Dysfunction

Beyond osmotic swelling, ammonia-induced glutamine accumulation leads to the mitochondrial permeability transition, increased oxidative stress, and astrocytic energy failure [135,136]. Advanced neuroimaging modalities like magnetic resonance spectroscopy (MRS) provide in vivo correlates, showing reduced N-acetyl-aspartate (NAA, a neuronal integrity marker), increased glutamine/glutamate peaks, and white matter changes that correlate with cognitive deficits in HE [137,138].

Clinical Implications and Therapeutic Insights

Understanding HE as a multifactorial neuroinflammatorymetabolic syndrome has expanded therapeutic approaches. Current management integrates nonabsorbable disaccharides (lactulose), non-systemic antibiotics (rifaximin), and nutritional support [139,140]. L-ornithine L-aspartate (LOLA) is used in some regions to enhance ammonia detoxification via residual urea cycle and glutamine synthesis pathways [141,142]. Maintenance of muscle mass through exercise and adequate protein intake is crucial, as skeletal muscle becomes an important alternative site for ammonia detoxification via glutamine synthesis in cirrhosis [143,144]. Emerging therapies focus on further modulating the gut microbiome, targeting neuroinflammation, and supporting astrocyte function [145,146].

Coagulopathy and Secondary Complications

Rebalanced Haemostasis in Cirrhosis

Cirrhosis profoundly alters the haemostatic system. The traditional view of a uniform hypocoagulable state has been replaced by the concept of a “rebalanced” yet fragile haemostatic equilibrium [147,148]. As the liver synthesizes nearly all procoagulant and anticoagulant factors, hepatic synthetic failure disrupts both sides of the clotting cascade. Levels of procoagulant factors (II, V, VII, IX, X, XI) and fibrinogen decline proportionally to hepatic dysfunction [149]. Concurrently, synthesis of natural anticoagulants-protein C, protein S, and antithrombin III-is also reduced [150]. Thrombocytopenia is common, arising primarily from portal hypertensive hypersplenism and, to a lesser extent, decreased thrombopoietin production [151,152]. Despite these deficiencies, global haemostatic function is often preserved or even enhanced due to compensatory increases. Factor VIII and von Willebrand factor (vWF) levels are markedly elevated due to endothelial activation and reduced clearance, promoting platelet adhesion and thrombin generation [153,154]. The net effect is a precarious balance that is easily perturbed by external factors like infection, renal failure, or procedures, explaining the paradoxical coexistence of bleeding and thrombotic events [155]. Standard coagulation tests (PT/INR, aPTT) are poor reflections of this in vivo balance; viscoelastic assays (thromboelastography [TEG], rotational thermoelectrometry [ROTEM]) provide a more comprehensive dynamic assessment [156].

Mechanisms of Bleeding and Thrombotic Tendencies

Bleeding in cirrhosis arises from a confluence of factors: portal hypertension (causing vascular fragility and varices), thrombocytopenia, platelet dysfunction, and, in some cases, hyperfibrinolysis [157]. Variceal haemorrhage is a direct consequence of ruptured high-pressure collaterals. Enhanced fibrinolysis can occur due to elevated tissue plasminogen activator (tPA) and decreased levels of its inhibitors (e.g., plasminogen activator inhibitor-1 [PAI-1], thrombin-activatable fibrinolysis inhibitor [TAFI]), leading to premature clot dissolution [158,159]. Thrombosis, particularly portal vein thrombosis (PVT), is increasingly recognized. A prothrombotic milieu is created by endothelial activation, reduced anticoagulant proteins, and sluggish portal flow [160]. Proinflammatory cytokines and elevated microparticles from activated platelets and monocytes further enhance thrombin generation [161]. Importantly, sinusoidal microthrombi are thought to contribute to parenchymal extinction and fibrosis progression, establishing a vicious cycle of thrombosis and fibrogenesis [162]. Anticoagulation with lowmolecular- weight heparin or direct oral anticoagulants (DOACs) can prevent PVT and may delay hepatic decompensation by modulating intrahepatic microcirculation [163,164].

Spontaneous Bacterial Peritonitis (SBP)

SBP is a classic example of a cirrhosis-specific infection, defined as ascitic fluid infection without an evident intraabdominal source. It occurs in up to 30% of hospitalized cirrhotic with ascites and carries significant mortality [165].

Pathogenesis hinges on the gut-liver axis:
a. Bacterial Translocation: Intestinal dysbiosis, increased gut permeability (“leaky gut”), and impaired local immunity allow bacteria, predominantly Gram-negative enteric organisms (E. coli, Klebsiella), to migrate to mesenteric lymph nodes and enter the systemic circulation [166-168].
b. Defective Ascitic Fluid Defense: The low protein content (<1.5 g/dL) of cirrhotic ascites results in deficient opsonic activity and complement levels, impairing bacterial phagocytosis [169].
c. Immune Dysfunction: Cirrhosis-associated immune dysfunction (CAID) leads to impaired neutrophil chemotaxis and phagocytic capacity, failing to clear translocated bacteria [170].

Diagnosis requires an ascitic polymorphonuclear (PMN) count ≥250 cells/mm³. Prophylaxis with norfloxacin or rifaximin reduces incidence by modulating gut flora, while albumin infusion during acute treatment prevents associated circulatory dysfunction and reduces mortality [171,172].

Hepatorenal Syndrome (HRS)

HRS is a functional, acute kidney injury occurring in advanced cirrhosis and ascites, characterized by intense renal vasoconstriction in the setting of systemic and splanchnic vasodilation [173]. The core mechanism is extreme activation of vasoconstrictor systems (RAAS, SNS, AVP) secondary to effective arterial hypovolemia from splanchnic arterial vasodilation [36,174]. An imbalance between renal vasodilators (prostaglandins, nitric oxide) and vasoconstrictors (endothelin-1, angiotensin II, adenosine) leads to profound renal hypoperfusion without structural injury [175,176]. Systemic inflammation and bacterial endotoxins are powerful precipitants and amplifiers, explaining the frequent association of HRS with infections like SBP [177]. Treatment with vasoconstrictors (terlipressin, norepinephrine) combined with albumin aims to reverse splanchnic vasodilation and improve renal perfusion, with liver transplantation remaining the definitive cure [79,178, 179].

Cirrhosis-Associated Immune Dysfunction (CAID)

CAID describes the paradoxical state of simultaneous systemic inflammation and immune paresis in cirrhosis [180,181]. Persistent exposure to gut-derived bacterial products leads to chronic innate immune activation (elevated cytokines like TNF-α, IL-6) but also causes immune cell exhaustion. Monocytes show reduced HLA-DR expression and blunted responses, while neutrophils exhibit impaired phagocytosis and oxidative burst [182,183]. This explains the high susceptibility to infections, poor vaccine responses, and the concept that infections can trigger a cascade of inflammation leading to multi-organ failure (acute-onchronic liver failure) [184]. Biomarkers like soluble CD163 and cytokine levels correlate with disease severity and mortality [185, 186].

Pathophysiology of Hepatocellular Carcinoma in Cirrhosis

Overview and Epidemiological Context

Hepatocellular carcinoma (HCC) represents the end-stage neoplastic transformation of chronically injured hepatocytes, with 80–90% of cases arising in the background of cirrhosis [187,188]. The cirrhotic liver provides a pro-oncogenic microenvironment characterized by chronic inflammation, oxidative stress, regenerative hyperplasia, and fibrotic remodeling. While viral hepatitis (HBV, HCV) remain dominant etiologies globally, metabolic dysfunction-associated steatitis liver disease (MASLD/ MASH) and alcohol-related liver disease are rapidly increasing contributors [189,190]. The risk of HCC correlates more strongly with the severity of fibrosis and inflammation than with etiology per se, underscoring fibrogenesis as a direct carcinogenic process [191,192].

The Fibrosis–Carcinogenesis Continuum

Hepatic stellate cells (HSCs) are pivotal in linking chronic injury to oncogenesis. Upon activation, HSCs transdifferentiate into myofibroblasts, producing excessive extracellular matrix (ECM) and secreting a plethora of growth factors and cytokines [193]. This fibrotic microenvironment actively promotes carcinogenesis through several mechanisms:
a) ECM Stiffening and Mechano-Signaling: Increased liver stiffness activates mechano-sensitive pathways in hepatocytes, most notably the Hippo/YAP pathway. Inactivation of the Hippo kinases allows YAP and TAZ to translocate to the nucleus, where they drive expression of genes promoting proliferation, survival, and epithelial-mesenchymal transition (EMT), effectively priming hepatocytes for transformation [194,195].
b) Paracrine Signaling from Activated HSCs: HSCs secrete pro-tumorigenic factors including vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF), and transforming growth factor-beta (TGF-β). These promote angiogenesis, hepatocyte proliferation, and invasion [196,197].
c) Inflammation and Immune Modulation: The fibrotic scar is rich in inflammatory cells and cytokines. Activated HSCs and Kupffer cells create an immunosuppressive niche by recruiting regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and by expressing immune checkpoint ligands like PDL1, enabling immune evasion of pre-malignant clones [198,199].

Oxidative Stress and DNA Damage

Chronic inflammation and impaired mitochondrial function in cirrhosis lead to sustained oxidative stress. Reactive oxygen species (ROS) and lipid peroxidation products (e.g., 4-hydroxynonenal) cause direct DNA damage, forming mutagenic adducts such as 8-oxoguanine and etheno-DNA bases [200]. This genomic instability drives mutations in key oncogenes and tumor suppressor genes. Furthermore, ROS activate redox-sensitive transcription factors like NF-κB and STAT3, which promote the expression of anti-apoptotic and pro-survival genes (Bcl-XL, cyclin D1) [201,202]. In viral etiologies, HBV X protein and HCV core protein exacerbate oxidative stress by impairing mitochondrial function and inducing NADPH oxidase activity [203,204].

Key Genetic and Epigenetic Alterations

Cirrhotic hepatocytes accumulate somatic mutations through cycles of injury and regeneration. Common driver mutations include:
I. TERT Promoter Mutations: The most frequent early event, leading to telomerase reactivation, cellular immortalization, and evasion of replicative senescence [205].
II. TP53 Mutations: Particularly the R249S mutation associated with aflatoxin B1 and HBV, leading to loss of cell-cycle control and genomic instability [206].
III. CTNNB1 (β-catenin) Mutations: Activating mutations stabilize β-catenin, leading to constitutive Wnt pathway activation, which drives proliferation and metabolic reprogramming (e.g., induction of glutaminolysis) [207,208].
IV. Chromatin Remodeling Genes (ARID1A, ARID2): Mutations in components of the SWI/SNF complex alter global gene expression programs to favor oncogenesis [209].

Epigenetic dysregulation via DNA methylation, histone modification, and non-coding RNA expression further silences tumor suppressors (e.g., CDKN2A, RASSF1A) and activates oncogenic pathways, contributing to HCC heterogeneity [210].

The Role of the Gut–Liver–Microbiome Axis

Emerging data implicate the gut microbiome as a modulator of hepatocarcinogenesis. Dysbiosis and increased intestinal permeability in cirrhosis lead to systemic exposure to bacterial products like lipopolysaccharide (LPS) and deoxycholic acid (DCA), a secondary bile acid [211,212]. LPS chronically activates TLR4 signaling on HSCs and Kupffer cells, sustaining a proinflammatory and pro-fibrogenic microenvironment [213]. DCA can cause DNA damage and induce a senescence-associated secretory phenotype (SASP) in hepatic stellate cells, which secretes factors that promote the growth of adjacent damaged hepatocytes [214]. This establishes a direct link between microbial metabolites and hepatic oncogenesis.

Angiogenesis and Vascular Remodeling

Cirrhosis-associated sinusoidal capillarization and hypoxia create a foundation for the abnormal angiogenesis characteristic of HCC. Hypoxia-inducible factor-1α (HIF-1α) stabilizes and upregulates pro-angiogenic factors like VEGF, angiopoietin-2, and fibroblast growth factor (FGF) [215,216]. The resultant tumor vasculature is disorganized, leaky, and inefficient, contributing to intra-tumoral hypoxia and further driving aggressive behavior. Therapeutic agents like sorafenib and Lenvatinib target this angiogenic signaling [217,218].

Metabolic Reprogramming

HCC cells undergo profound metabolic reprogramming to support rapid proliferation. This includes a shift to aerobic glycolysis (the Warburg effect), increased glutaminolysis, and enhanced lipogenesis [219]. Upregulation of key enzymes like hexokinase 2 (HK2), pyruvate kinase M2 (PKM2), and fatty acid synthase (FASN) is driven by oncogenic pathways (PI3K/AKT/ mTOR, c-Myc) and provides biosynthetic precursors [220,221]. This metabolic adaptability is a potential therapeutic vulnerability.

Conceptual Model of Progression

The transition from cirrhosis to HCC can be viewed as a multistep process: chronic injury → regeneration and low-grade dysplasia → high-grade dysplastic nodules → early HCC → progressed HCC. This progression is fueled by the accumulation of genetic hits within a permissive microenvironment of inflammation, fibrosis, and immune suppression [222]. Histologically, the transition is marked by loss of the reticulin framework, increasing cell density, unpaired arteries, and stromal invasion [223].

Etiologic Pathways: Distinct Triggers, Convergent Pathophysiology

While cirrhosis is a common histological endpoint, the initiating injury and early pathophysiological mechanisms vary significantly by etiology, influencing the pace of progression, histologic pattern, and associated systemic features. Understanding these distinctions is crucial for targeted prevention and therapy.

Alcohol-Related Liver Disease (ALD)

Pathophysiology: Direct hepatotoxicity is mediated by ethanol metabolism, which generates acetaldehyde and reactive oxygen species (ROS) via cytochrome P450 2E1 (CYP2E1) and alcohol dehydrogenase pathways. This leads to lipid peroxidation, mitochondrial dysfunction, and endoplasmic reticulum stress [224]. Acetaldehyde also promotes hepatic stellate cell (HSC) activation and collagen synthesis. Concurrently, gut-derived endotoxemia activates Kupffer cells via TLR4, resulting in a potent pro-inflammatory cytokine release (TNF-α, IL-1β, IL-6) that drives necroinflammation and fibrosis [225]. Histology typically shows steatosis, hepatocyte ballooning, Mallory-Denk bodies, and pericentral (zone 3) fibrosis progressing to micronodular cirrhosis. Clinically, ALD is marked by episodes of acute-onchronic decompensation with jaundice and encephalopathy during binge drinking, often accompanied by signs of malnutrition and peripheral neuropathy [226].

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) / Steatohepatitis (MASH)

Pathophysiology: Driven by insulin resistance and lip toxicity. Hepatic fat accumulation (steatosis) results from an imbalance between fatty acid uptake, de novo lipogenesis, and fatty acid oxidation. Lipotoxic species (free fatty acids, diacylglycerols, ceramides) cause hepatocyte injury, mitochondrial dysfunction, and oxidative stress [227]. This activates inflammatory pathways (NF-κB, JNK) and inflammasomes (NLRP3), leading to the recruitment of immune cells and the transition to steatohepatitis (MASH). Injured hepatocytes and activated Kupffer cells release profibrogenic mediators (TGF-β, PDGF) that activate HSCs [228]. Histology reveals macro vesicular steatosis, lobular inflammation, hepatocyte ballooning, and perisinusoidal (chicken-wire) fibrosis. Clinically, it is often indolent and associated with features of metabolic syndrome (obesity, type 2 diabetes, dyslipidemia). Notably, significant portal hypertension and HCC risk can develop even before overt cirrhosis is established [229, 230].

Viral Hepatitis (HBV and HCV)

a. Chronic Hepatitis B (CHB): Pathogenesis involves a complex interplay between viral replication and host immune response. Continuous immune-mediated hepatocyte lysis leads to chronic inflammation, regeneration, and fibrosis. The integrated HBV DNA can cause insertional mutagenesis, while the viral HBx protein disrupts cellular signaling, promotes genomic instability, and inhibits DNA repair, directly contributing to carcinogenesis [231].
b. Chronic Hepatitis C (HCV): The virus exhibits direct cytopathic effects and induces a strong yet ineffective immune response. HCV core and non-structural proteins promote oxidative stress, insulin resistance, and steatosis. Persistent inflammation leads to progressive bridging fibrosis. HCV is also strongly associated with extrahepatic manifestations like mixed cryoglobulinemia [232].
c. Clinical Presentation: HBV cirrhosis can have an insidious onset with fluctuating ALT levels. HCV cirrhosis often presents with fatigue, arthralgias, and later features of portal hypertension.

Autoimmune and Cholestatic Liver Diseases

a) Autoimmune Hepatitis (AIH): Characterized by a loss of immune tolerance to hepatocyte antigens, leading to a CD4+ T-cell mediated interface hepatitis with plasma cell infiltration. Untreated, it progresses to bridging fibrosis and cirrhosis [233].
b) Primary Biliary Cholangitis (PBC): An autoimmune disorder targeting intrahepatic bile duct epithelial cells, leading to granulomatous cholangitis, progressive ductopenia, cholestasis, and eventually biliary-type fibrosis and cirrhosis. Antimitochondrial antibodies (AMA) are a hallmark [234].
c) Primary Sclerosing Cholangitis (PSC): Involves fibro-obliterative inflammation of intra- and extra-hepatic bile ducts, leading to multifocal strictures, cholestasis, and a high risk of cholangiocarcinoma. There is a strong association with inflammatory bowel disease (IBD) [235].

Genetic and Metabolic Disorders/b>

I. Hereditary Hemochromatosis: Mutations in the HFE gene lead to unregulated intestinal iron absorption. Iron overload in hepatocytes catalyzes the Fenton reaction, generating hydroxyl radicals that cause oxidative DNA and organelle damage, triggering apoptosis and fibrosis, typically in a pericellular and periportal pattern [236].
II. Wilson Disease: Mutations in the ATP7B gene impair biliary copper excretion, leading to hepatic copper accumulation. Copper promotes oxidative stress and mitochondrial injury, resulting in steatosis, inflammation, and progressive fibrosis [237].
III. Alpha-1 Antitrypsin Deficiency: The Z variant (Glu342Lys) of the SERPINA1 gene leads to polymerization and retention of misfolded alpha-1 antitrypsin protein within hepatocyte endoplasmic reticulum. This causes proteotoxic stress (ER stress), autophagy impairment, and chronic hepatocyte injury, culminating in fibrosis and an increased risk of HCC [238].

Conclusion and Future Directions

Cirrhosis represents the final common pathway of chronic liver injury, culminating in profound structural remodeling, altered hemodynamics, and multisystem dysfunction [239]. The clinical manifestations-portal hypertension, jaundice, ascites, hepatic encephalopathy, coagulopathy, and their complications-arise from a complex, integrated pathophysiology rather than isolated hepatic failure. Over the past two decades, our understanding has shifted from viewing cirrhosis as a static, irreversible scar to recognizing it as a dynamic and potentially modifiable disease process [240].

Integrated Systems Perspective

Cirrhosis is now recognized as a systemic disorder. The development of cirrhosis-associated immune dysfunction (CAID) explains the unique susceptibility to infection. Cirrhotic cardiomyopathy and hepatorenal syndrome underscore the interorgan consequences of splanchnic vasodilation and neurohumoral activation. The concept of the gut-liver-brain axis has become central to understanding hepatic encephalopathy and systemic inflammation. This systems biology view is essential for holistic patient management.

Therapeutic Implications and Emerging Frontiers

Traditional management focused on treating complications. Contemporary and future approaches aim to target the root pathophysiologic drivers:
a) Portal Pressure Reduction & Anti-fibrotic: nonselective β-blockers, statins, and emerging agents targeting TGF-β, LOXL2, and galectin-3 aim to modify the disease course [241,242].
b) Gut-Liver Axis Modulation: Rifaximin, FXR agonists (e.g., Obet cholic acid), probiotics, and fecal microbiota transplantation (FMT) are being explored to restore microbial homeostasis, reduce bacterial translocation, and dampen inflammation [243,244].
c) Immunomodulation: Strategies to correct CAID, such as granulocyte colony-stimulating factor (G-CSF) or targeted antiinflammatory agents, are under investigation to reduce infection risk and improve outcomes [245].
d) HCC Prevention and Treatment: Beyond surveillance, chemo preventive strategies (e.g., statins, aspirin) are being studied. For established HCC, combination immunotherapy (immune checkpoint inhibitors) with anti-angiogenic agents represents a paradigm shift [246].

Precision Hepatology and Prognostic Modelling

The future lies in precision medicine. Integrating multiomic data (genomics, transcriptomics, microbiomics) with advanced imaging and clinical parameters will enable molecular subtyping of cirrhosis, predicting individual risks for decompensation or HCC [247]. Artificial intelligence and machine learning models are being developed to provide dynamic, personalized risk estimation and guide therapy [248]. Novel prognostic tools like MELD 3.0 and CLIF-C scores already incorporate more holistic parameters [249,250].

Concluding Synthesis

In summary, the pathophysiology of the clinical manifestations of liver cirrhosis reflects an exquisitely interconnected network of cellular injury, vascular remodeling, immune activation, and metabolic reprogramming. Understanding these mechanisms not only clarifies the basis of symptoms but also identifies critical leverage points for intervention. Cirrhosis is not a terminal state but a biologically active, dynamic condition amenable to stabilization or even partial reversal if its mechanistic underpinnings are targeted early and comprehensively. Future research must continue to integrate molecular insights with clinical practice, emphasizing multi-system pathophysiology and personalized therapeutics to redefine outcomes in this complex disease.

References

  1. Schuppan D, Afdhalppan NH (2008) Liver cirrhosis. Lancet 371(9615): 838-851.
  2. Asrani SK, Devarbhavi H, Eaton J, Kamath PS (2019) Burden of liver diseases in the world. J Hepatol 70(1): 151-171.
  3. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, et al. (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1): 73-84.
  4. Mack CL, Adams D, Assis DN (2020) Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology 72(2): 671-722.
  5. Friedman SL (2008) Mechanisms of hepatic fibrogenesis. Gastroenterology 134(6): 1655-1669.
  6. Bataller R, Brenner DA (2005) Liver fibrosis. J Clin Invest 115(2): 209-218.
  7. Hernández-Gea V, Friedman SL (2011) Pathogenesis of liver fibrosis. Annu Rev Pathol 6: 425-456.
  8. DeLeve LD (2015) Liver sinusoidal endothelial cells in hepatic fibrosis. Hepatology 61(5): 1740-1746.
  9. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V, et al. (2015) Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol 63(5): 1272-1284.
  10. Albillos A, Martín-Mateos R, Van der Merwe S, Wiest R, Jalan R, et al. (2022) Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol 19(2):112-134.
  11. D'Amico G, Garcia-Tsao G, Pagliaro L (2006) Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol 44(1): 217-231.
  12. Ginès P, Quintero E, Arroyo V (1987) Compensated cirrhosis: natural history and prognostic factors. Hepatology 7(1): 122-128.
  13. Northup PG, Garcia-Pagan JC, Garcia-Tsao G (2021) Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 73(1): 366-413.
  14. Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H, et al. (2010) Clinical course of alcoholic liver cirrhosis: A Danish population-based cohort study. Hepatology 51(5): 1675-1682.
  15. Runyon BA (2013) Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 57(4): 1651-1653.
  16. Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V, et al. (2007) Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 56(9): 1310-1318.
  17. Forner A, Reig M, Bruix J (2018) Hepatocellular carcinoma. Lancet 391(10127): 1301-1314.
  18. Groszmann RJ, Garcia-Tsao G (2005) Portal hypertension: from bedside to bench. J Clin Gastroenterol 39(4 Suppl 2): S125-30.
  19. Ripoll C, Groszmann R, Garcia-Tsao G (2007) Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133(2): 481-488.
  20. de Franchis R, Baveno VI Faculty (2015) Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol 63(3): 743-752.
  21. García-Pagán JC, Gracia-Sancho J, Bosch J (2012) Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol 57(2): 458-461.
  22. Kisseleva T, Brenner D (2021) Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol 18(3): 151-166.
  23. Tsuchida T, Friedman SL (2017) Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol 14(7): 397-411.
  24. Pinzani M, Gesualdo L, Sabbah GM, Abboud HE (1989) Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest 84(6): 1786-1793.
  25. Rockey DC, Chung JJ (1998) Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 114(2): 344-351.
  26. Iwakiri Y (2012) Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int 32(2):199-213.
  27. Abraldes JG, Rodríguez-Vilarrupla A, Graupera M (2007) Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. J Hepatol 46(6): 1040-1046.
  28. Thabut D, Shah V (2010) Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol 53(5): 976-980.
  29. Anstee QM, Dhar A, Thursz MR (2011) The role of hypercoagulability in liver fibrogenesis. Clin Res Hepatol Gastroenterol 35(8-9): 526-533.
  30. Villa E, Cammà C, Marietta M (2012) Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 143(5): 1253-1260.e4.
  31. Wiest R, Groszmann RJ (2002) The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35(2): 478-491.
  32. Gupta TK, Toruner M, Chung MK, Groszmann RJ (1998) Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 28(4): 926-931.
  33. Bernardi M Trevisani F, Gasbarrini A, Gasbarrini G (1994) Hepatorenal disorders: role of the renin-angiotensin-aldosterone system. Semin Liver Dis 14(1): 23-34.
  34. Henriksen JH, Møller S (2001) Hemodynamics, distribution of blood volume, and kinetics of vasoactive substances in cirrhosis. Gastroenterology 120(4): 1058-1061.
  35. Gines P, Berl T, Bernardi M (1998) Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 28(3): 851-864.
  36. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, et al. (1988) Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8(5): 1151-1157.
  37. Møller S, Bendtsen F (2018) The pathophysiology of arterial vasodilation and hyperdynamic circulation in cirrhosis. Liver Int 38(4): 570-580.
  38. Fernández M, Mejías M, Angermayr B, García-Pagán JC, Rodés J, et al. (2005) Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol 43(1): 98-103.
  39. Geerts AM, Vanheule E, Praet M (2008) Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation. Int J Exp Pathol 89(4): 251-263.
  40. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, et al. (2009) Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 49(4): 1245-1256.
  41. Tugues S, Fernandez-Varo G, Muñoz-Luque J (2007) Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46(6): 1919-1926.
  42. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W (2007) Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 46(3): 922-938.
  43. Villanueva C, Colomo A, Bosch A (2013) Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 368(1): 11-21.
  44. Meng XM, Nikolic-Paterson DJ, Lan HY (2016) TGF-β: the master regulator of fibrosis. Nat Rev Nephrol 12(6): 325-338.
  45. Choi SS, Omenetti A, Witek RP (2009) Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol 297(6): G1093-1106.
  46. Seki E, De Minicis S, Österreicher CH (2007) TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 13(11): 1324-1332.
  47. Wiest R, Lawson M, Geuking M (2014) Pathological bacterial translocation in liver cirrhosis. J Hepatol 60(1): 197-209.
  48. Bellot P, García-Pagán JC, Francés R(2010) Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology 52(6): 2044-2052.
  49. De Minicis S, Seki E, Paik YH (2010) Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis. Hepatology 52(4): 1420-1430.
  50. Nieto N (2006) Oxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cells. Hepatology 44(6): 1487-1501.
  51. Bosch J, Garcia Tsao G (2009) Pharmacological versus endoscopic therapy in the prevention of variceal hemorrhage: and the winner is. Hepatology 50(3): 674-677.
  52. Boyer TD, Haskal ZJ (2010) The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology 51(1): 306.
  53. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, et al. (2007) Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46(1): 242-253.
  54. Meissner EG, McLaughlin M, Matthews L, Gharib AM, Wood BJ, et al. (2016) Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. Liver Int 36(12): 1783-1792.
  55. Roy Chowdhury J, Roy Chowdhury N (2018) Bilirubin metabolism and its disorders. In: Zakim and Boyer's Hepatology. 7th ed. Elsevier 898-925.
  56. Sauerbruch T, Hennenberg M, Trebicka J, Beuers U (2021) Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. Front Physiols 12: 718783.
  57. Ginès P, Krag A, Abraldes JG (2021) Diagnosis and management of decompensated cirrhosis. Nat Rev Gastroenterol Hepatol 18(1): 3-20.
  58. Thakkar N, Slizgi JR, Brouwer KLR (2017) Effect of Liver Disease on Hepatic Transporter Expression and Function. J Pharm Sci 106(9): 2282-2294.
  59. Pan Q, Zhu G, Xu Z, Zhu J, Ouyang J, et al. (2023) Organic Anion Transporting Polypeptide (OATP) 1B3 is a Significant Transporter for Hepatic Uptake of Conjugated Bile Acids in Humans. Cell Mol Gastroenterol Hepatol 16(2): 223-242.
  60. Park SC, Kim YJ, Kim JW (2024) Targeting uridine diphosphate glucuronosyltransferase 1A1 in liver disease: Current research and future directions. World J Gastroenterol 30(39): 4305-4307.
  61. Sticova E, Jirsa M (2013) New insights in bilirubin metabolism and their clinical implications. World J Gastroenterol 19(38): 6398-6407.
  62. Li T, Apte U (2015) Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer. Adv Pharmacol 74: 263-302.
  63. Şenol A, Alayunt NÖ, Solmaz ÖA (2021) Role of tumor necrosis factor-α, interleukin-1β, interleukin-6 in liver inflammation in chronic hepatitis B and chronic hepatitis C. Gulhane Med J 63(3): 200-204.
  64. Neuman M, Angulo P, Malkiewicz I, Jorgensen R, Shear N, et al. (2002) Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J Gastroenterol Hepatol 17(2): 196-202.
  65. John YL Chiang (2017) Bile acid metabolism and signaling in liver disease and therapy. Liver Res 1(1): 3-9.
  66. Stofan M, Guo GL (2020) Bile Acids and FXR: Novel Targets for Liver Diseases. Front Med (Lausanne) 7: 544.
  67. Beuers U, Kremer AE, Bolier R, Elferink RP (2014) Pruritus in cholestasis: facts and fiction. Hepatology 60(1): 399-407.
  68. Ramírez-Mejía MM, Castillo-Castañeda SM, Pal SC, Qi X, Méndez-Sánchez N (2024) The Multifaceted Role of Bilirubin in Liver Disease: A Literature Review. J Clin Transl Hepatol 12(11): 939-948.
  69. López-Velázquez JA, Chávez-Tapia NC, Ponciano-Rodríguez G, Sánchez-Valle V, Caldwell SH, et al. (2014) Bilirubin alone as a biomarker for short-term mortality in acute-on-chronic liver failure: an important prognostic indicator. Ann Hepatol 13(1): 98-104.
  70. Pedersen JS, Bendtsen F, Møller S (2015) Management of cirrhotic ascites. Ther Adv Chronic Dis 6(3): 124-137.
  71. Cárdenas A, Arroyo V (2003) Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinol Metab 17(4): 607-622.
  72. Elisa Pose, Andres Cardenas (2017) Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention. Dig Dis 35(4): 402–410.
  73. Gibert-Ramos A, Sanfeliu-Redondo D, Aristu-Zabalza P, et al. (2021) The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer. Cancers (Basel) 13(22): 5719.
  74. Pettersson A, Nagy JA, Brown LF, C Sundberg, E Morgan, et al. (2000) Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor. Lab Invest 80(1): 99-115.
  75. Fountain JH, Kaur J, Lappin SL (2024) Physiology, Renin Angiotensin System. StatPearls;
  76. Ishikawa S (2017) Is Exaggerated Release of Arginine Vasopressin an Endocrine Disorder? Pathophysiology and Treatment. J Clin Med 6(11): 102.
  77. Rahman SN, Abraham WT, Schrier RW (1992) Peripheral arterial vasodilation hypothesis in cirrhosis. Gastroenterology International 5(3): 192-195.
  78. Bansal S, Badesch D, Bull T, Schrier RW (2009) Role of vasopressin and aldosterone in pulmonary arterial hypertension: A pilot study. Contemp Clin Trials 30(5): 392-399.
  79. Rajekar H, Chawla Y (2011) Terlipressin in hepatorenal syndrome: Evidence for present indications. J Gastroenterol Hepatol 26 Suppl 1:109-14.
  80. Sherman M, DiSilvio B, Cheema T (2025) Overview and management of hepatorenal syndrome. Curr Opin Anaesthesiol 38(4): 492-497.
  81. Rivolta R, Maggi A, Cazzaniga M, D Castagnone, A Panzeri, et al. (1998) Reduction of renal cortical blood flow assessed by Doppler in cirrhotic patients with refractory ascites. Hepatology 28(5): 1235-1240.
  82. Ross S, Thometz D, Serafini F, Bloomston M, Morton C, et al. (2009) Renal haemodynamics and function following partial portal decompression. HPB (Oxford) 11(3): 229-234.
  83. Ilan Y (2012) Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis. World J Gastroenterol 18(21): 2609-18.
  84. Shahed FHM, Mamun-Al-Mahtab, Rahman S (2016) The Evaluation of Serum Ascites Albumin Gradient and Portal Hypertensive changes in Cirrhotic Patients with Ascites. Euroasian J Hepatogastroenterol 6(1): 8-9.
  85. Runyon BA (2013) Management of adult patients with ascites due to cirrhosis: update 2012. Hepatology 57(4): 1651-1653.
  86. Kwong AJ, Norman J, Biggins SW (2024) Management of ascites and volume overload in patients with cirrhosis. Clin Liver Dis (Hoboken) 23(1): e0115.
  87. Aithal GP, Palaniyappan N, China L, Härmälä S, Macken L, et al. (2021) Guidelines on the management of ascites in cirrhosis. Gut 70(1): 9-29.
  88. Kumar R, Anand U, Priyadarshi RN (2021) Lymphatic dysfunction in advanced cirrhosis: Contextual perspective and clinical implications. World J Hepatol 13(3): 300-314.
  89. Bernardi M, Maggi A, Trevisani F, et al. (2012) Therapeutic role of albumin in cirrhosis. J Hepatol 57(1): 1-7.
  90. Engelmann C, Clària J, Szabo G, Bosch J, Bernardi M (2021) Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. J Hepatol 75 Suppl 1: S49-S66.
  91. Perri GA (2013) Ascites in patients with cirrhosis. Can Fam Physician 59(12): 1297-9.
  92. Lenz K, Buder R, Kapun L, Voglmayr M (2015) Treatment and management of ascites and hepatorenal syndrome: an update. Therap Adv Gastroenterol 8(2): 83-100.
  93. Gentilini P, Casini-Raggi V, Di Fiore G, R G Romanelli, G Buzzelli, et al. (1999) Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 30(4): 639-45.
  94. Madoff DC, Cornman-Homonoff J, Fortune BE, et al. (2021) Management of Refractory Ascites Due to Portal Hypertension: Current Status. Radiology 298(3): 493-504.
  95. Gao Y, Liu X, Gao Y, Duan M, Hou B, et al. (2024) Pharmacological Interventions for Cirrhotic Ascites: From Challenges to Emerging Therapeutic Horizons. Gut Liver 18(6): 934-948.
  96. Rodrigues SG, Yuly P Mendoza, Jaime Bosch (2020) Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Reports 2(1): 100063.
  97. Rose CF, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, et al. (2020) Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. J Hepatol 73(6): 1526-1547.
  98. Song J, Lu W, Yang S, Wu F, Zhao Z, Ji J (2025) Effects of shunt embolization on hepatic encephalopathy recurrence in patients with major portosystemic shunts: A systematic review and meta analysis. Biomed Rep 22(4): 72.
  99. Ferenci P (2017) Hepatic encephalopathy. Gastroenterol Rep (Oxf) 5(2): 138-147.
  100. Lizardi-Cervera J, Almeda P, Guevara L, Uribe M (2003) Hepatic encephalopathy: A review. Ann Hepatol 2(3): 122-130.
  101. Claeys W, Van Hoecke L, Lefere S (2021) The neuroglia vascular unit in hepatic encephalopathy. JHEP Reports 3(5): 100352.
  102. Morales-Galicia AE, Rincón-Sánchez MN, Ramírez-Mejía MM, Méndez-Sánchez N (2025) How the gut-liver axis shapes hepatic encephalopathy: mechanistic and therapeutic perspectives. Explor Dig Dis 4: 100597.v
  103. Ashwin W, Deva R, Girish C (2025) Paradigm shifts in hepatic encephalopathy: Review of recent therapeutic breakthroughs. World J Meta-Anal 13(3): 108018.
  104. Walker V (2014) Ammonia Metabolism and Hyperammonemia Disorders. Adv Clin Chem 67: 73-150.
  105. Deutsch-Link S, Moon AM, Jiang Y, Barritt AS 4th, Tapper EB (2022) Serum Ammonia in Cirrhosis: Clinical Impact of Hyperammonemia, Utility of Testing, and National Testing Trends. Clin Ther 44(3): e45-e57.
  106. Blanco Vela CI, Bosques Padilla FJ (2011) Determination of ammonia concentrations in cirrhosis patients-still confusing after all these years? Ann Hepatol 10 Suppl 2: S60-S65.
  107. Goldbecker A, Buchert R, Berding G (2010) Blood-brain barrier permeability for ammonia in patients with different grades of liver fibrosis is not different from healthy controls. J Cereb Blood Flow Metab 30(7): 1384-1393.
  108. Zielińska M, Popek M, Albrecht J (2014) Roles of changes in active glutamine transport in brain edema development during hepatic encephalopathy: an emerging concept. Neurochemical Res 39(3): 599-604.
  109. Albrecht J, Zielińska M, Norenberg MD (2010) Glutamine as a mediator of ammonia neurotoxicity: A critical appraisal. Biochem Pharmacol 80(9): 1303-1308.
  110. Rama Rao KV and Norenberg MD (2014) Glutamine in the pathogenesis of hepatic encephalopathy: the Trojan horse hypothesis revisited. neurochemical Res 39(3): 593-598.
  111. Ochoa-Sanchez R and Rose CF (2018) Pathogenesis of Hepatic Encephalopathy in Chronic Liver Disease. J Clin Exp Hepatol 8(3): 262-271.
  112. Butterworth RF (2016) Neurosteroids in hepatic encephalopathy: Novel insights and new therapeutic opportunities. J Steroid Biochem Mol Biol 160: 94-97.
  113. Limón ID, Angulo-Cruz I, Sánchez-Abdon L, Patricio-Martínez A (2021) Disturbance of the Glutamate-Glutamine Cycle, Secondary to Hepatic Damage, Compromises Memory Function. Front Neurosci 15: 578922.
  114. Mehkari Z, Mohammed L, Javed M (2020) Manganese, a Likely Cause of 'Parkinson's in Cirrhosis', a Unique Clinical Entity of Acquired Hepatocerebral Degeneration. Cureus 12(9): e10448.
  115. Burkhard PR, Delavelle J, Du Pasquier R, Spahr L (2003) Chronic parkinsonism associated with cirrhosis: a distinct subset of acquired hepatocerebral degeneration. Arch Neurol 60(4): 521-528.
  116. Tranah TH, Vijay GK, Ryan JM, Shawcross DL (2013) Systemic inflammation and ammonia in hepatic encephalopathy. Metab Brain Dis 28(1): 1-5.
  117. Ntuli Y and Shawcross DL (2024) Infection, inflammation and hepatic encephalopathy from a clinical perspective. Metab Brain Dis 39(8): 1689-1703.
  118. Hernández-Rabaza V, Cabrera-Pastor A, Taoro-González L (2016) Hyperammonemia induces glial activation, neuroinflammation and alters neurotransmitter receptors in hippocampus, impairing spatial learning: reversal by sulforaphane. J Neuroinflammation 13: 41.
  119. Ismail FS, Faustmann TJ, Corvace F (2021) Ammonia induced microglia activation was associated with limited effects on connexin 43 and aquaporin 4 expression in an astrocyte-microglia co-culture model. BMC Neurosci 22(1): 21.
  120. Kosenko E, Tikhonova L, Alilova G, Montoliu C (2022) Is NMDA-Receptor-Mediated Oxidative Stress in Mitochondria of Peripheral Tissues the Essential Factor in the Pathogenesis of Hepatic Encephalopathy? J Clin Med 11(3): 827.
  121. Chastre A, Bélanger M, Beauchesne E (2012) Inflammatory cascades driven by tumor necrosis factor-alpha play a major role in the progression of acute liver failure and its neurological complications. PLoS One 7(11): e49670.
  122. Odeh M (2007) Pathogenesis of hepatic encephalopathy: the tumour necrosis factor-alpha theory. Eur J Clin Invest 37(4):291-304.
  123. Won SM, Oh KK, Gupta H (2022) The Link between Gut Microbiota and Hepatic Encephalopathy. Int J Mol Sci 23(16): 8999.
  124. Wu JL, Chen JW, Huang MS (2024) The causal effect of gut microbiota on hepatic encephalopathy: a mendelian randomization analysis. BMC Med Genomics 17(1): 216.
  125. Gómez-Hurtado I, Such J, Sanz Y, Francés R (2014) Gut microbiota-related complications in cirrhosis. World J Gastroenterol 20(42): 15624-15631.
  126. Dazıroğlu and Merve (2023) Intestinal dysbiosis and probiotic use: its place in hepatic encephalopathy in cirrhosis. Ann Gastroenterol 36(2): 141-148.
  127. Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F (2024) Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med 19(2): 275-293.
  128. Usami M, Miyoshi M, Yamashita H (2015) Gut microbiota and host metabolism in liver cirrhosis. World J Gastroenterol 21(41): 11597-11608.
  129. Bass NM, Mullen KD, Sanyal A (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362(12): 1071-1081.
  130. Ponziani FR, Gerardi V, Pecere S (2015) Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol 21(43): 12322-12333.
  131. Paik YH, Lee KS, Han KH (2005) Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study. Yonsei Med J 46(3): 399-407.
  132. Dalal R, McGee RG, Riordan SM, Webster AC (2017) Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev 2(2): CD008716.
  133. Zhou L, Pu T, Xiao B, Luo J, Xue L (2024) Meta-analysis of probiotics efficacy in the treatment of minimum hepatic encephalopathy. Liver Int 44(12): 3164-3173.
  134. Shah YR, Ali H, Tiwari A (2024) Role of fecal microbiota transplant in management of hepatic encephalopathy: Current trends and future directions. World J Hepatol 16(1): 17-32.
  135. Niknahad H, Jamshidzadeh A, Heidari R, Zarei M, Ommati MM (2017) Ammonia-induced mitochondrial dysfunction and energy metabolism disturbances in isolated brain and liver mitochondria, and the effect of taurine administration: relevance to hepatic encephalopathy treatment. Clin Exp Hepatol 3(3): 141-151.
  136. Drews L, Zimmermann M, Westhoff P (2020) Ammonia inhibits energy metabolism in astrocytes in a rapid and glutamate dehydrogenase 2-dependent manner. Dis Model Mech 13(10): dmm047134.
  137. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM (2007) N-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 81(2): 89-131.
  138. Ramadan S, Lin A, Stanwell P (2013) Glutamate and glutamine: a review of in vivo MRS in the human brain. NMR Biomed 26(12): 1630-1646.
  139. Hoilat GJ, Suhail FK, Adhami T, John S (2022) Evidence-based approach to management of hepatic encephalopathy in adults. World J Hepatol 14(4): 670-681.
  140. Gluud LL, Dam G, Borre M (2013) Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? Metab Brain Dis 28(2): 221-225.
  141. Butterworth RF, McPhail MJW (2019) L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses. Drugs 79(Suppl 1): 31-37.
  142. Jain A, Sharma BC, Mahajan B (2022) L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial. Hepatology 75(5): 1194-1203.
  143. Di Cola S, Nardelli S, Ridola L, Gioia S, Riggio O, et al. (2022) Ammonia and the Muscle: An Emerging Point of View on Hepatic Encephalopathy. J Clin Med 11(3): 611.
  144. Wongtrakul W, Bandidniyamanon W, Charatcharoenwitthaya P (2025) Relationship between Sarcopenia and minimal hepatic encephalopathy in patients with cirrhosis: a prospective observational study. BMC Gastroenterol 25(1): 88.
  145. Santos RPC, Toscano ECB, Rachid MA (2023) Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies. Arq Neuropsiquiatr 81(7): 656-669.
  146. Hasan LZ, Wu GY (2021) Novel Agents in the Management of Hepatic Encephalopathy: A Review. J Clin Transl Hepatol 9(5): 749-759.
  147. Lisman T, Hernandez-Gea V, Magnusson M (2021) The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. J Thromb Haemost 19(4): 1116-1122.
  148. Tripodi A, Primignani M, Chantarangkul V (2009) The coagulopathy of cirrhosis assessed by thermoelectrometry and its correlation with conventional coagulation parameters. Thromb Res 124(1): 132-136.
  149. Senzolo M, Burra P, Cholongitas E, Burroughs AK (2006) New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 12(48): 7725-7736.
  150. Caldwell SH, Hoffman M, Lisman T (2006) Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 44(4): 1039-1046.
  151. Mitchell O, Feldman DM, Diakow M, Sigal SH (2016) The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med 8: 39-50.
  152. Radosavljevic MP (2017) Thrombocytopenia in chronic liver disease. Liver Int 37(6): 778-793.
  153. Sundd TP, Gudapati S, Kaminski TW, Ragni MV (2021) Exploring the Complex Role of Coagulation Factor VIII in Chronic Liver Disease. Cell Mol Gastroenterol Hepatol 12(3): 1061-1072.
  154. Violi F, Basili S, Raparelli V, Chowdary P, Gatt A, et al. (2011) Patients with liver cirrhosis suffer from primary haemostatic defects? Fact or fiction. J Hepatol 55(6): 1415-1427.
  155. Rautou PE, Caldwell SH, Villa E (2023) Bleeding and Thrombotic Complications in Patients with Cirrhosis: A State-of-the-Art Appraisal. Clin Gastroenterol Hepatol 21(8): 2110-2123.
  156. Mallett SV, Chowdary P, Burroughs AK (2013) Clinical utility of viscoelastic tests of coagulation in patients with liver disease. Liver Int 33(7): 961-974.
  157. Intagliata NM, Argo CK, Stine JG, Lisman T, Caldwell SH, et al. (2018) Concepts and Controversies in Haemostasis and Thrombosis Associated with Liver Disease: Proceedings of the 7th International Coagulation in Liver Disease Conference. Thromb Haemost 118(8): 1491-1506.
  158. Rijken DC, Kock EL, Guimarães AH, Talens S, Murad SD, et al. (2012) Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 10(10): 2116-2122.
  159. Blasi A, Patel VC, Adelmeijer J, Azarian S, Tejero MH, et al. (2020) Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acute-on-Chronic Liver Failure with Hypofibrinolysis in Those with Complications and Poor Survival. Hepatology 71(4): 1381-1390.
  160. Prakash S, Bies J, Hassan M, Mares A, Didia SC (2023) Portal vein thrombosis in cirrhosis: A literature review. Front Med (Lausanne) 10: 1134801.
  161. Stravitz RT, Bowling R, Bradford RL, Key NS, Glover S, et al. (2013) Role of procoagulant microparticles in mediating complications and outcome of acute liver injury/acute liver failure. Hepatology 58(1): 304-313.
  162. Airola C, Pallozzi M, Cerrito L, Santopaolo F, Stella L, et al. (2023) Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications. Cells 12(13): 1712.
  163. Pereira Portela C, Gautier LA, Zermatten MG, Fraga M, Moradpour D, et al. (2024) Direct oral anticoagulants in cirrhosis: Rationale and current evidence. JHEP Reports 6(8): 101116.
  164. European Association for the Study of the Liver (2022) EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol 76(5): 1151-1184.
  165. Hung TH, Wang CY, Tsai CC, Lee HF (2024) Short and long-term mortality of spontaneous bacterial peritonitis in cirrhotic patients. Medicine (Baltimore) 103(50): e40851.
  166. Maslennikov R, Poluektova E, Zolnikova O, Sedova A, Kurbatova A, et al. (2023) Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis. Int J Mol Sci 24(22): 16502.
  167. Imge Ucar B, Ucar G (2021) Intestinal Barrier Dysfunction, Bacterial Translocation and Inflammation: Deathly Triad in Sepsis. In: Infections and Sepsis Development. Intech Open.
  168. Fiore M, Di Franco S, Alfieri A, Passavanti MB, Pace MC, et al. (2020) Spontaneous bacterial peritonitis due to carbapenemase-producing Enterobacteriaceae: Etiology and antibiotic treatment. World J Hepatol 12(12): 1136-1147.
  169. Lutz P, Nischalke HD, Strassburg CP, Spengler U (2015) Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver. World J Hepatol 7(3): 304-314.
  170. Bonnel AR, Bunchorntavakul C, Reddy KR (2011) Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol 9(9):727-738.
  171. Salerno F, Navickis RJ, Wilkes MM (2013) Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 11(2): 123-130.
  172. Poca M, Concepción M, Casas M, Urturi CA, Gordillo J, et al. (2012) Role of albumin treatment in patients with spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol 10(3): 309-315.
  173. Salerno F, Angeli P, Ginès P, Wong F (2015) Diagnosis and management of hepatorenal syndrome in cirrhosis. Hepatology 62(4): 1520-1531.
  174. Martell M, Coll M, Ezkurdia N, Raurell I, Genescà J (2010) Physiopathology of splanchnic vasodilation in portal hypertension. World J Hepatol 2(6): 208-220.
  175. Badura K, Frąk W, Hajdys J, Majchrowicz G, Młynarska E, et al. (2023) Hepatorenal Syndrome-Novel Insights into Diagnostics and Treatment. Int J Mol Sci 24(24): 17469.
  176. Gines P, Guevara M, Arroyo V, Rodés J (2003) Hepatorenal syndrome. Lancet 362(9398): 1819-1827.
  177. Choudhury A, Kulkarni AV, Arora V, Soin AS, Dokmeci AK, et al. (2025) Acute-on-chronic liver failure (ACLF): the 'Kyoto Consensus'-steps from Asia. Hepatol Int 19(1): 1-69.
  178. Allegretti AS, Patidar KR, Ma AT, Cullaro G (2025) From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury. Hepatology 81(6): 1878-1897.
  179. Yuren ASO, Reyes EC, Maceda MRH, Narro GC (2021) An integrated review of the Hepatorenal syndrome. Ann Hepatol.
  180. Irvine KM, Ratnasekera I, Powell EE, Hume DA (2019) Causes and Consequences of Innate Immune Dysfunction in Cirrhosis. Front Immunol 10: 293.
  181. McGettigan B, Bruns T, Moreau R, Shah V (2025) Immune Dysfunction and Infection Risk in Advanced Liver Disease. Gastroenterology 168(6): 1085-1100.
  182. Liu T, Chouik Y, Lebossé F, Khamri W (2023) Dysfunctions of Circulating Adaptive Immune Cells in End-Stage Liver Disease. Livers 3(3): 369-382.
  183. Ferguson Toll J, Solà E, Perez MA, Piano S, Cheng A, et al. (2024) Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda. Hepatol Commun 8(10): e0539.
  184. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, et al. (2013) Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144(7): 1426-1437.
  185. Bossen L, Lau TS, Nielsen MB, Nielsen MC, Andersen AH, et al. (2023) The association between soluble CD163, disease severity, and ursodiol treatment in patients with primary biliary cholangitis. Hepatol Commun 7(4): e0068.
  186. Møller HJ, Grønbaek H, Schiødt FV, Fischer PH, Schilsky M, et al. (2007) Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J Hepatol 47(5): 671-676.
  187. Bengtsson B, Widman L, Wahlin S, Stål P, Björkström NK, et al. (2022) The risk of hepatocellular carcinoma in cirrhosis differs by etiology, age and sex: A Swedish nationwide population-based cohort study. United European Gastroenterol J 10(5): 465-476.
  188. Tarao K, Nozaki A, Ikeda T, Sato A, Komatsu H, et al. (2019) Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. Cancer Med 8(3): 1054-1065.
  189. Zhou DQ, Liu JY, Zhao F (2024) Risk factors for hepatocellular carcinoma in cirrhosis: A comprehensive analysis from a decade-long study. World J Gastrointest Oncol 16(12): 4625-4635.
  190. Younossi ZM, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, et al. (2019) Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol 17(4): 748-755.
  191. Zhang DY, Friedman SL (2012) Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 56(2): 769-775.
  192. Chen L, Ye X, Yang L, Zhao J, You J, et al. (2024) Linking fatty liver diseases to hepatocellular carcinoma by hepatic stellate cells. J Natl Cancer Cent 4(1): 25-35.
  193. Garbuzenko DV (2022) Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis. World J Clin Cases 10(12): 3662-3676.
  194. Mannaerts I, Leite SB, Verhulst S, Claerhout S, Eysackers N, et al. (2015) The Hippo pathway effector YAP controls mouse hepatic stellate cell activation. J Hepatol 63(3): 679-688.
  195. Passi M, Zahler S (2021) Mechano-Signaling Aspects of Hepatocellular Carcinoma. J Cancer 12(21): 6411-6421.
  196. Coulouarn C, Clément B (2014) Stellate cells and the development of liver cancer: therapeutic potential of targeting the stroma. J Hepatol 60(6): 1306-1309.
  197. Cucarull B, Tutusaus A, Rider P, Alsina TH, Cuño C (2022) Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers (Basel) 14(3): 621.
  198. Tümen D, Heumann P, Gülow K, Demirci CN, Cosma LS, et al. (2022) Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. Biomedicines 10(12): 3202.
  199. Zheng J, Wang S, Xia L, Sun Z, Chan KM, et al. (2025) Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal Trans duct Target Ther 10(1): 35.
  200. Gentile F, Arcaro A, Pizzimenti S, Daga M, Cetrangolo GP, et al. (2017) DNA damage by lipid peroxidation products: implications in cancer, inflammation and autoimmunity. AIMS Genetics 4(2): 103-137.
  201. Krajka-Kuźniak V, Belka M, Papierska K (2024) Targeting STAT3 and NF-κB Signaling Pathways in Cancer Prevention and Treatment: The Role of Chalcones. Cancers (Basel) 16(6): 1092.
  202. Grivennikov SI, Karin M (2010) Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21(1): 11-19.
  203. Agustiningsih A, Rasyak MR, Turyadi JS, Sukowati C (2024) The oncogenic role of hepatitis B virus X gene in hepatocarcinogenesis: recent updates. Explor Target Antitumor Ther 5: 120–134.
  204. Li Y, Boehning DF, Qian T, Popov VL, Weinman SA (2007) Hepatitis C virus core protein increases mitochondrial ROS production by stimulation of Ca2+ uniporter activity. FASEB J 21(10): 2474-2485.
  205. Nault JC, Mallet M, Pilati C (2013) High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 4: 2218.
  206. Chittmittrapap S, Chieochansin T, Chaiteerakij R (2013) Prevalence of aflatoxin induced p53 mutation at codon 249 (R249s) in hepatocellular carcinoma patients with and without hepatitis B surface antigen (HBsAg). Asian Pac J Cancer Prev 14(12): 7675-7679.
  207. Wang W, Smits R, Hao H, He C (2019) Wnt/β-Catenin Signaling in Liver Cancers. Cancers (Basel) 11(7): 926.
  208. Song P, Gao Z, Bao Y (2024) Wnt/β-catenin signaling pathway in carcinogenesis and cancer therapy. J Hematol Oncol 17(1): 46.
  209. (2017) Cancer Genome Atlas Research Network. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 169(7): 1327-1341.
  210. Lin HY, Jeon AJ, Chen K (2025) The epigenetic basis of hepatocellular carcinoma — mechanisms and potential directions for biomarkers and therapeutics. Br J Cancer 132: 869–887.
  211. Xie C, Pocha C (2023) Crosstalk between Gut Microbiota and Hepatocellular Carcinoma. Gastrointest Disord 5(2): 127-143.
  212. Daniel N, Genua F, Jenab M (2024) The role of the gut microbiome in the development of hepatobiliary cancers. Hepatology 80(5): 1252-1269.
  213. Dapito DH, Mencin A, Gwak GY (2012) Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21(4): 504-516.
  214. Song Y, Lau HC, Zhang X, Yu J (2023) Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma. Cancer Biol Med 20(12): 894-909.
  215. Chen JA, Shi M, Li JQ, Qian CN (2010) Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. Hepatol Int 4(3): 537-547.
  216. Pinto E, Pelizzaro F, Farinati F, Russo FP (2023) Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies. Medicina (Kaunas) 59(6): 1115.
  217. Gajos-Michniewicz A, Czyz M (2023) WNT/β-catenin signaling in hepatocellular carcinoma: The aberrant activation, pathogenic roles, and therapeutic opportunities. Genes Dis 11(2): 727-746.
  218. Wang L, Liu WQ, Broussy S, Han B, Fang H (2024) Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis. Front Pharmacol 14: 1307860.
  219. Gnocchi D, Sabbà C, Massimi M, Mazzocca A (2023) Metabolism as a New Avenue for Hepatocellular Carcinoma Therapy. Int J Mol Sci 24(4): 3710.
  220. Zhang S, Liao Z, Li S, Luo Y (2023) Non-metabolic enzyme function of PKM2 in hepatocellular carcinoma: A review. Medicine (Baltimore) 102(42): e35571.
  221. Schiliro C, Firestein BL (2021) Mechanisms of Metabolic Reprogramming in Cancer Cells Supporting Enhanced Growth and Proliferation. Cells 10(5): 1056.
  222. Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R (2013) From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer 2(3-4): 367-383.
  223. International Consensus Group for Hepatocellular Neoplasia (2009) Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49(2): 658-664.
  224. Gao B, Bataller R (2011) Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 141(5): 1572-1585.
  225. Mackowiak B, Fu Y, Maccioni L, Gao B (2024) Alcohol-associated liver disease. J Clin Invest 134(3): e176345.
  226. Singal AK, Bataller R, Ahn J, Kamath PS, Shah VH (2018) ACG Clinical Guideline: Alcoholic Liver Disease. Am J Gastroenterol 113(2): 175-194.
  227. Berlanga A, Guiu-Jurado E, Porras JA, Auguet T (2014) Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol 7: 221-239.
  228. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ (2018) Mechanisms of NAFLD development and therapeutic strategies. Nat Med 24(7): 908-922.
  229. Younossi ZM, Stepanova M, Rafiq N (2011) Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 53(6): 1874-1882.
  230. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M (2019) From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol 16(7): 411-428.
  231. Seeger C, Mason WS (2015) Molecular biology of hepatitis B virus infection. Virology 480: 672-686.
  232. Poynard T, Mathurin P, Lai CL (2003) A comparison of fibrosis progression in chronic liver diseases. J Hepatol 38(3): 257-265.
  233. Mack CL, Adams D, Assis DN (2020) Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology 72(2): 671-722.
  234. Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M (2019) Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology 69(1): 394-419.
  235. Karlsen TH, Folseraas T, Thorburn D, Vesterhus M (2017) Primary sclerosing cholangitis - a comprehensive review. J Hepatol 67(6): 1298-1323.
  236. Girelli D, Busti F, Brissot P, Cabantchik I, Muckenthaler MU (2022) Hemochromatosis classification: update and recommendations by the BIOIRON Society. Blood 139(20): 3018-3029.
  237. Roberts EA, Schilsky ML (2008) Diagnosis and treatment of Wilson disease: an update. Hepatology 47(6): 2089-2111.
  238. Fromme M, Schneider CV, Porsch M (2022) Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder. J Hepatol 76(4): 946-958.
  239. Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N (2021) Liver cirrhosis. Lancet 398(10308): 1359-1376.
  240. Zúñiga-Aguilar E, Ramírez-Fernández O (2022) Fibrosis and hepatic regeneration mechanism. Transl Gastroenterol Hepatol 7: 9.
  241. Trebicka J, Hennenberg M, Laleman W (2015) Statins in portal hypertension---mechanistic basis and clinical data. J Hepatol 62(3): 820–831.
  242. Trautwein C, Friedman SL, Schuppan D, Pinzani M (2015) Hepatic fibrosis: Concept to treatment. J Hepatol 62(1 Suppl): S15-S24.
  243. Adorini L, Trauner M, Nevens F (2023) FXR agonists in NASH treatment. J Hepatol 79(5): 1317-1331.
  244. Bajaj JS, Kassam Z, Fagan A (2017) Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology 66(6): 1727-1738.
  245. Engelmann C, Sheikh M, Sharma S (2020) Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure. J Hepatol 73(1): 102-112.
  246. Finn RS, Qin S, Ikeda M (2020) Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382(20): 1894-1905.
  247. Hoshida Y, Villanueva A, Sangiovanni A (2013) Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 144(5): 1024-1030.
  248. Zhai Y, Hai D, Zeng L (2024) Artificial intelligence-based evaluation of prognosis in cirrhosis. J Transl Med 22(1): 933.
  249. Nagel M, Westphal R, Hilscher M (2023) Validation of the CLIF-C OF Score and CLIF-C ACLF Score to Predict Transplant-Free Survival in Patients with Liver Cirrhosis and Concomitant Need for Intensive Care Unit Treatment. Medicina (Kaunas) 59(5): 866.
  250. Perdigoto DN, Figueiredo P, Tomé L (2019) The Role of the CLIF-C OF and the 2016 MELD in Prognosis of Cirrhosis with and without Acute-on-Chronic Liver Failure. Ann Hepatol 18(1): 48-57.



© 2015-2026 juniper publishers, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by Juniper Publishers is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at www.juniperpublishers.com.
Best viewed in browser_icons browser_icons | Above IE 7.0 version | Privacy Policy